Members of the Senate Finance Committee yesterday questioned President Trump’s pick to head CMS over what she plans to do about a subject that’s on everybody’s mind: high drug prices. Trump wants CMS to step in and negotiate drug prices for Medicare Part D plans, and the need to get those costs under control is one issue that all sides of the political spectrum seems to agree on. Verma danced around the subject, as STAT reports, not actually saying that she’d like to see the sort of government negotiating leverage over drug prices similar to what’s allowed by the Department of Veterans Affairs.   

According to STAT, she told legislators: “I think that competition is the key to getting good prices. I don’t think that’s a simple yes or no answer, because I think there are many ways to achieve that goal. … If we look at the Part D program and the way the PBMs have negotiated this, we know that when there’s a lot of competition, the price goes down.”

Verma, 46, is CEO and founder of SVC, a national health policy consulting company. Verma helped develop the report, “A New Medicaid: A Flexible, Innovation and Accountable Future,” that was presented to the Republican Governor’s Public Policy Committee on Medicaid reform in 2011.

Source: STAT

 

More Headlines

A couple of other steps may be waiting in the wings
The problem could undercut years of progress
New single-tablet regiment indicated for genotypes 1 to 6
Stop short of recommending public policy efforts
But they may be inching that way
Medicaid expansion looks safe for now, but nothing else is certain
Paratek is planning to submit an application in the first quarter of 2018
Neither replacing nor repealing the act have the votes they need